4,068 posters, 219 videos, 101 topics, 69 sessions, 14,365 authors, 6,128 institutions
ePostersLive by SciGen Technologies S.A. All rights reserved.
Alzheimer's Association International Conference 2026
July 12-15, 2026 | London, United Kingdom, and Online
13216
Evolution of Real-World Blood-Based Biomarker Use in the Lecanemab Patient Pathway: Three-Year Update From the LEADER Study
Poster Presenter
Authors
Cara Leahy, Brent Berry, Christian Camargo, Tinatin Chabrashvili, Gregory Cooper, Nick Frost, Sam Giles, Michael Rosenbloom, Marwan Noel Sabbagh, Martin Sadowski, Curtis Schreiber, Paul Schulz, Jose Soria, Babak Tousi, David Weisman, Kimberly Petro, Courtney Adams, Daryl Rhys Jones
Affiliations
Cleveland Clinic, Cleveland, OH, USA, Barrow Neurological Institute, Phoenix, AZ, USA, Eisai Inc., Nutley, NJ, USA, University of Miami Miller School of Medicine, Miami, FL, USA, Memorial Healthcare Institute for Neuroscience, Owosso, MI, USA, Minneapolis Clinic of Neurology, Minneapolis, MN, USA, SUNY Upstate Medical University, NY, USA, Norton Neuroscience Institute, Louisville, KY, USA, University of Utah Department of Neurology, Salt Lake City, UT, USA, Memory Treatment Centers, Jacksonville Beach, FL, USA, University of Washington, Seattle, WA, USA, NYU Langone Health, New York, NY, USA, Missouri Memory Center, Citizens Memorial Hospital, Bolivar, MO, USA, The McGovern Medical School of UTHealth-Houston, Houston, TX, USA, The Neuron Clinic, San Marcos, CA, USA, Abington Neurological Associates, Abington, PA, USA
Part of Topic
Drug Development -> Human -> Real-world Data / Real-world Evidence
Summary:
Keywords: Blood-based biomarkers; Lecanemab; p-tau217; Aβ42/40; Real-world implementation
Comments
Email is required but is not shown publicly.
Loading comments...